Abbreviations

Abbreviations

GMB

Adult glioblastoma

pHGG

Paediatric high-grade glioma

UNCAN

EU initiative for understanding cancer

MRI

Magnetic resonance imaging 

SOC

Standard of care

I/O

Immuno-oncology

TTF

Tumour treating fields

Spatial proteomics named 2024 Method of the Year by Nature Methods

Spatial proteomics has been named 2024 Method of the Year by Nature Methods. This technique, which maps protein distributions within tissues with high resolution, is central to the GLIOMATCH project, where we use it to study the glioblastoma tumour microenvironment.

Key contributions to this work come from Frederik De Smet’s lab at KU Leuven, through the KU Leuven Institute for Single Cell Omics (LISCO), which holds expertise in multiplex immunohistochemistry (mIHC), advanced bioinformatics, and cutting-edge spatial mapping technologies like MILAN, Phenocycler, and COMET by Lunaphore. Meanwhile, Aspect Analytics supports the integration of multi-omics data from various spatial proteomics platforms, enabling a comprehensive understanding of tissue biology and protein interactions.

To find out more about how GLIOMATCH uses spatial proteomics, visit our project and work plan pages.

Follow GLIOMATCH on LinkedIn and Facebook for more information on brain tumour research and updates on our milestones towards improving the clinical outcomes of GBM and pHGG.

More Posts

GLIOMATCH: Explained with Prof. Dr. Sandra Jacobs

In this GLIOMATCH: Explained episode, Prof. Dr. Sandra Jacobs introduces the paediatric clinical study, the participating centres and the challenges of working with archived samples from paediatric high-grade glioma patients.

GLIOMATCH marks World Brain Tumour Day at EU event on advancing brain cancer research

On World Brain Tumour Day 2026, GLIOMATCH participated in the European event “Advancing Brain Cancer Research: From policy action to scientific breakthroughs” at the European Parliament in Strasbourg. The event highlighted the urgent need to accelerate brain cancer research, strengthen European collaboration and turn scientific progress into improved care for patients.

GLIOMATCH: Explained with Prof. Dr. Steven De Vleeschouwer

In this GLIOMATCH: Explained episode, Prof. Dr. Steven De Vleeschouwer introduces the prospective clinical trials, the participating centres and the immunotherapy strategies being investigated to better understand patient response in brain tumours.

GLIOMATCH 5th consortium meeting takes place in Barcelona

On 28–29 April 2026, the GLIOMATCH consortium gathered in Barcelona, Spain, for its fifth consortium meeting, hosted by project partner Sant Joan de Déu Barcelona Children’s Hospital and the Fundació de Recerca Sant Joan de Déu (FSJD).